Dosing & Administration
KORSUVA® IS DELIVERED AS A SIMPLE IV BOLUS AT THE END OF HAEMODIALYSIS (HD)1
KORSUVA® can be administered as part of your patient's in-centre HD routine:*1
KORSUVA® is administered three times per week at the end of HD treatment†1
The recommended dose of KORSUVA® is 0.5 μg/kg dry body weight1
KORSUVA® is administered as a simple IV bolus injection into the venous line
of the dialysis circuit during rinse-back or after rinse-back‡1
- When given after rinse back, at least 10 mL of sodium chloride 9 mg/mL (0.9%) solution rinse-back volume should be administered after injection of KORSUVA®
- If the dose is given during rinse back, no additional sodium chloride 9 mg/mL (0.9%) solution is needed to flush the line
KORSUVA® INJECTION VOLUMES1
The total dose volume (mL) required from the vial should be calculated as: 0.01 × dry body weight (kg), rounded to the nearest tenth (0.1 mL).1
Dosing is the same for elderly patients aged ≥65 years as adult patients.§1
No dose adjustment is required for patients with mild or moderate hepatic impairment.¶1
PLEASE NOTE
- KORSUVA® should not be diluted or mixed with other medicinal products
- Vials are for single-use only, discard any unused product
- KORSUVA® should be a clear, colourless solution, free from particles. Inspect for any particulate matter or discolouration before administration
References & footnotes
Footnotes
*KORSUVA® administration should be restricted for in-centre HD only and is intended for use by HCPs experienced in the diagnosis and treatment of moderate-to-severe CKD-associated Pruritus. Causes of pruritus other than CKD should be excluded before initiating treatment with KORSUVA®.
†If a regular HD treatment is missed, KORSUVA® should be administered at the next HD treatment. For HD treatments less than 1 hour, administration of KORSUVA® should be withheld until the next haemodialysis session. If a 4th HD treatment is performed in a week KORSUVA® should be administered at the end of the HD per the recommended dose. No more than 4 doses per week should be administered even if the number of HD treatments administered in a week exceeds 4. A 4th dose of KORSUVA® is unlikely to lead to accumulation of KORSUVA® that would be of concern for safety, as the majority of remaining KORSUVA® from the previous treatment will be cleared by HD. However, safety and efficacy of a 4th dose has not been fully established due to insufficient data.
‡KORSUVA® is removed by the dialyzer membrane and must be administered after blood is no longer circulating through the dialyzer.
§The safety and efficacy of KORSUVA® in children aged 0-17 years has not yet been established. No data is available.
¶KORSUVA® has not been studied in subjects with severe hepatic impairment (National Cancer Institute Organ Dysfunction Working Group) and is therefore not recommended for use in this patient population.
Abbreviations
CKD, chronic kidney disease; CKD-associated Pruritus, Chronic Kidney Disease-associated Pruritus; HD, haemodialysis; IV, intravenous.
References
GCC-DFK-2500011 | Date of preparation: October 2025